[Use of the antioxidant ubinon in the complex treatment of patients with ischemic heart disease].
A new Soviet antioxidant drug, ubinon, has been used in 75 patients with coronary heart disease (CHD) of functional classes I-III, including 12 patients with ventricular extrasystoles. Treatment with placebo in 10 patients produced no improvement and had no effect on their stress tolerance. Ubinon, taken as 90 and 135 mg/day doses, was shown to produce clinical improvement and raise stress tolerance, mostly in first- and second-class cases. In coronary patients with ventricular extrasystoles, ubinon enhanced antiarrhythmic effect of mexitil. The use of ubinon was accompanied by a drop in blood oxidant activity and a rise in antioxidant activity, an increase in blood 6-keto-PGF1 alpha, a fall in TxB2 and a suppression of platelet activity. In addition, coronary patients with ventricular extrasystoles showed reduced cAMP and cGMP content and elevated cAMP/cGMP ratio.
Dudaev
V A
VA
Borodkin
V V
VV
Abbud
A
A
Diukov
I V
IV
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D010919:Placebos
D000975:Antioxidants; D010919:Placebos; D005996:Nitroglycerin
Primenenie antioksidanta ubinona v kompleksnom lechenii bo'lnykh ishemicheskoĭ bolez'niu serdtsa.